Chemclin Diagnostics Co., Ltd. (SHA:688468)
China
· Delayed Price · Currency is CNY 7.41
+0.17 (2.35%)
Apr 29, 2026, 3:00 PM CST
Chemclin Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 332.68 | 436.29 | 445.34 | 465.27 | 470.77 | Upgrade
|
| Revenue Growth (YoY) | -23.75% | -2.03% | -4.28% | -1.17% | 12.57% | Upgrade
|
| Cost of Revenue | 111.52 | 113.12 | 110.56 | 121.11 | 119.84 | Upgrade
|
| Gross Profit | 221.16 | 323.17 | 334.78 | 344.16 | 350.94 | Upgrade
|
| Selling, General & Admin | 105.04 | 136.61 | 133.41 | 135.17 | 143.23 | Upgrade
|
| Research & Development | 73.31 | 73.74 | 65.14 | 68.36 | 66.78 | Upgrade
|
| Other Operating Expenses | -3.75 | 5.38 | 5.03 | 5.49 | 3.66 | Upgrade
|
| Operating Expenses | 174.61 | 215.53 | 203.17 | 209.05 | 213.82 | Upgrade
|
| Operating Income | 46.55 | 107.65 | 131.61 | 135.11 | 137.12 | Upgrade
|
| Interest Expense | - | -5.24 | -0.47 | -0.52 | -0.73 | Upgrade
|
| Interest & Investment Income | 8.84 | 19.79 | 22.04 | 25.03 | 18.29 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.07 | 0.08 | 0.4 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.84 | -0.09 | -0.15 | -0.08 | -0.42 | Upgrade
|
| EBT Excluding Unusual Items | 58.24 | 122.18 | 153.12 | 159.93 | 154.13 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.22 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.12 | 0.06 | 0.14 | -0.62 | -0.64 | Upgrade
|
| Asset Writedown | -9.76 | -3.67 | -2.8 | -1.46 | -0.32 | Upgrade
|
| Other Unusual Items | - | 19.35 | 15.66 | 19.51 | 9.02 | Upgrade
|
| Pretax Income | 49.82 | 137.92 | 166.12 | 177.37 | 162.19 | Upgrade
|
| Income Tax Expense | 5.91 | 10.84 | 18.75 | 24.74 | 19.43 | Upgrade
|
| Net Income | 43.91 | 127.07 | 147.37 | 152.63 | 142.76 | Upgrade
|
| Net Income to Common | 43.91 | 127.07 | 147.37 | 152.63 | 142.76 | Upgrade
|
| Net Income Growth | -65.44% | -13.77% | -3.44% | 6.91% | 21.99% | Upgrade
|
| Shares Outstanding (Basic) | 399 | 397 | 398 | 402 | 386 | Upgrade
|
| Shares Outstanding (Diluted) | 399 | 397 | 398 | 402 | 386 | Upgrade
|
| Shares Change (YoY) | 0.53% | -0.30% | -0.83% | 4.10% | 8.80% | Upgrade
|
| EPS (Basic) | 0.11 | 0.32 | 0.37 | 0.38 | 0.37 | Upgrade
|
| EPS (Diluted) | 0.11 | 0.32 | 0.37 | 0.38 | 0.37 | Upgrade
|
| EPS Growth | -65.63% | -13.51% | -2.63% | 2.70% | 12.12% | Upgrade
|
| Free Cash Flow | 24.01 | 60.46 | -128.32 | 119.28 | 116.31 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.15 | -0.32 | 0.30 | 0.30 | Upgrade
|
| Dividend Per Share | - | 0.125 | 0.125 | 0.347 | 0.170 | Upgrade
|
| Dividend Growth | - | - | -63.98% | 104.12% | - | Upgrade
|
| Gross Margin | 66.48% | 74.07% | 75.17% | 73.97% | 74.54% | Upgrade
|
| Operating Margin | 13.99% | 24.67% | 29.55% | 29.04% | 29.13% | Upgrade
|
| Profit Margin | 13.20% | 29.13% | 33.09% | 32.80% | 30.32% | Upgrade
|
| Free Cash Flow Margin | 7.22% | 13.86% | -28.81% | 25.64% | 24.71% | Upgrade
|
| EBITDA | 93.49 | 153.7 | 168.77 | 175.19 | 179.97 | Upgrade
|
| EBITDA Margin | 28.10% | 35.23% | 37.90% | 37.65% | 38.23% | Upgrade
|
| D&A For EBITDA | 46.94 | 46.05 | 37.16 | 40.08 | 42.84 | Upgrade
|
| EBIT | 46.55 | 107.65 | 131.61 | 135.11 | 137.12 | Upgrade
|
| EBIT Margin | 13.99% | 24.67% | 29.55% | 29.04% | 29.13% | Upgrade
|
| Effective Tax Rate | 11.86% | 7.86% | 11.29% | 13.95% | 11.98% | Upgrade
|
| Revenue as Reported | - | 436.29 | 445.34 | 465.27 | 470.77 | Upgrade
|
| Advertising Expenses | - | 4.06 | 6.63 | 4.1 | 6.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.